|
Symbol Name ID |
Gucy2c
guanylate cyclase 2c MGI:106903 |
| Allelic Composition Genetic Background |
Annotated Term | Reference |
| Gucy2ctm1Gar/Gucy2ctm1Gar B6.129S6-Gucy2ctm1Gar |
cardiac hypertrophy | J:178241 |
| hepatic steatosis | J:178241 | |
| impaired glucose tolerance | J:178241 | |
| increased body weight | J:178241 | |
| increased circulating insulin level | J:178241 | |
| increased circulating leptin level | J:178241 | |
| increased compensatory feeding amount | J:178241 | |
| increased heart weight | J:178241 | |
| increased liver triglyceride level | J:178241 | |
| increased subcutaneous adipose tissue amount | J:178241 | |
| increased total body fat amount | J:178241 | |
| polyphagia | J:178241 | |
| Gucy2ctm1Gar/Gucy2ctm1Gar either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * C57BL/6J) |
decreased susceptibility to bacterial infection | J:43046 |
| decreased susceptibility to bacterial infection induced morbidity/mortality | J:43046 | |
| diarrhea | J:43046 | |
| Gucy2ctm1Gian/Gucy2ctm1Gian involves: 129P2/OlaHsd * Black Swiss |
decreased susceptibility to infection | J:43682 |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 09/30/2025 MGI 6.24 |
|
|
|
||